Noninvasive evaluation of PD-L1 expression in non-small cell lung cancer by immunoPET imaging using an acylating agent–modified antibody fragment

Cheng, Yuan; Shi, Dai; Ye, Renjie; Fu, Wenhui; Ma, Ping; Si, Zhan; Xu, Zhan; Li, Lixin; Lin, Qingyu; Cheng, Dengfeng

doi:10.1007/s00259-023-06130-6

Eur J Nucl Med Mol Imaging

2023

DOI: 10.1007/s00259-023-06130-6

|View full text |Cite

Noninvasive evaluation of PD-L1 expression in non-small cell lung cancer by immunoPET imaging using an acylating agent–modified antibody fragment

Yuan Cheng

Dai Shi

Renjie Ye

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Next Generation of Solid Target Radionuclide Antibody Conjugates for Tumor Immuno‐Therapy

Hou,

Kong,

Yao

et al. 2024

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Immune checkpoint therapy has emerged as an effective treatment option for various types of cancers. Key immune checkpoint molecules, such as cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), programmed cell death protein 1 (PD‐1), and lymphocyte activation gene 3 (LAG‐3), have become pivotal targets in cancer immunotherapy. Antibodies designed to inhibit these molecules have demonstrated significant clinical efficacy. Nevertheless, the ability to monitor changes in the immune status of tumors and predict treatment response remains limited. Conventional methods, such as assessing lymphocytes in peripheral blood or conducting tumor biopsies, are inadequate for providing real‐time, spatial information about T‐cell distributions within heterogeneous tumors. Positron emission tomography (PET) using T‐cell specific probes represents a promising and noninvasive approach to monitor both systemic and intratumoral immune changes during treatment. This technique holds substantial clinical significance and potential utility. In this paper, we review the applications of PET probes that target immune cells in molecular imaging.

show abstract

Next Generation of Solid Target Radionuclide Antibody Conjugates for Tumor Immuno‐Therapy

Hou,

Kong,

Yao

et al. 2024

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

show abstract

Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy

Zhu,

Liang,

Zhou

et al. 2023

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

A novel 68Ga-labeled cyclic peptide molecular probe based on the computer-aided design for noninvasive imaging of PD-L1 expression in tumors

Ge,

Zhang,

et al. 2023

Bioorganic Chemistry

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Noninvasive evaluation of PD-L1 expression in non-small cell lung cancer by immunoPET imaging using an acylating agent–modified antibody fragment

Cited by 3 publications

References 31 publications

Next Generation of Solid Target Radionuclide Antibody Conjugates for Tumor Immuno‐Therapy

Next Generation of Solid Target Radionuclide Antibody Conjugates for Tumor Immuno‐Therapy

Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy

A novel 68Ga-labeled cyclic peptide molecular probe based on the computer-aided design for noninvasive imaging of PD-L1 expression in tumors

Contact Info

Product

Resources

About